Condition: HIV - Human Immunodeficiency Virus · Sponsor: Cara Spence
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Sheldon M Chumir Health Centre | Calgary, Alberta, Canada | Not Yet Recruiting |
| Queen City Wellness Pharmacy | Regina, Saskatchewan, Canada | Not Yet Recruiting |
| Mayfair Drugs Pharmacy | Saskatoon, Saskatchewan, Canada | Recruiting |
| Pharmasave Riversdale Pharmacy | Saskatoon, Saskatchewan, Canada | Recruiting |
| The Medicine Shoppe Pharmacy | Saskatoon, Saskatchewan, Canada | Recruiting |
| Meadowgreen Pharmacy | Saskatoon, Saskatchewan, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07160075